Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06352359 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by OncoC4.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 8
- Study locations
NCT06352359 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by OncoC4. The registered enrollment target is 30 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (84% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT06352359, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by OncoC4.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase I open label, dose-escalation study of intravenous (IV) infusion of ONC-841 as a single agent in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841 starting from 0.03 mg/kg to 30 mg/kg.
Conditions Studied
Interventions
- DRUG ONC-841
Study Locations (8)
Florida
- UF Health Cancer Center, University of Florida - Gainesville
- AdventHealth Medical Group Oncology Research at Celebration - Kissimmee
Texas
- MD Anderson Cancer Center - Houston
- Tranquil Clinical Research - Houston
California
- University of California at Davis Cancer Center - Sacramento
Kentucky
- Norton Cancer Center - Louisville
Michigan
- Rogel Cancer Center, University of Michigan - Ann Arbor
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-23 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06352359
The ClinicalTrials.gov registry entry for NCT06352359 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (84% lower). The listed sponsor is OncoC4, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ONC-841 is the first listed.
NCT06352359 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Florida, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06352359 about?
NCT06352359 is a clinical study titled "Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors". This is a Phase I open label, dose-escalation study of intravenous (IV) infusion of ONC-841 as a single agent in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841 starting from 0.03 mg/kg to 30 mg/kg.
What is the current status of trial NCT06352359?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-08-23. Estimated completion is 2027-09-30.
What conditions does trial NCT06352359 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06352359?
The interventions under investigation include: ONC-841 (DRUG).
Who is sponsoring clinical trial NCT06352359?
This trial is sponsored by OncoC4, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06352359 being conducted?
This trial has 8 study locations across California, Florida, Kentucky, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.